Biodistribution of doxorubicin-alkylated poly(L-lysine citramide imide) conjugates in an experimental model of peritoneal carcinomatosis after intraperitoneal administration

被引:22
作者
Colombo, Pierre-Emmanuel
Boustta, Mahfoud
Poujol, Sylvain
Pinguet, Frederic
Rouanet, Philippe
Bressolle, Francoise
Vend, Michel
机构
[1] Ctr Reg Lutte Contre Canc, Dept Surg Oncol, F-34298 Montpellier 5, France
[2] Ctr Reg Lutte Contre Canc, Lab Oncopharmacol, F-34298 Montpellier, France
[3] Univ Montpellier 1, Clin Pharmacokinet Lab, F-34093 Montpellier 5, France
[4] Univ Montpellier 1, Fac Pharm, CNRS, UMR 5473,Rs Ctr Artificial Polymers, F-34093 Montpellier 5, France
关键词
peritoneal carcinomatosis; doxorubicin drug delivery systems; macromolecular prodrug; poly(L-lysine citramide imide); polymer therapeutics; antitumoral;
D O I
10.1016/j.ejps.2007.02.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Peritoneal spread is a common manifestation in ovarian and gastrointestinal cancer. Intraperitoneal (i.p.) chemotherapy after cytoreductive surgery is associated with high systemic or local toxicity. A macromolecular drug delivery system was evaluated with the aim of improving the therapeutic index of i.p. chemotherapy Peritoneal carcinomatosis was generated in BDIX rats (n=55) by i.p. injection of 2 million DHDK12 cells. Fourteen days later, doxorubicin (DOX) and two DOX-alkylated poly(L-lysine citramide imide) conjugates bearing 9.5% and 20.5% (w/w) chemically bound drug, respectively, were given Lp. to rats at a single 2 mg DOX/kg dose. Free and polymer-bound DOX were assessed in plasma, peritoneal fluid, abdominal tissues and heart, IS min, 2, 6, 24,48 and 168 h after injection. According to pharmacokinetic profiles, the peritoneal fluid areas under the concentration versus time curves (AUCs) were 2 and 2.6 times greater for the conjugates (P-DOX20 and P-DOX10, respectively) than for the free drug, respectively. Conjugates crossed the peritoneal barrier slower than the free drug. For the tumor, AUCs were, respectively, 3 and 7 times higher for the conjugates than for free DOX. The elimination half-lives of the conjugates were higher than that calculated for the free drug. Only very small concentrations were detected in peripheral organs and in the heart. In contrast, significant retention and accumulation of the conjugates were found in abdominal organs, particularly in the tumor. There was no sign of macroscopic chemical peritonitis after injection of the polymer-DOX conjugates. In conclusion, the conjugates have higher elimination half-lives than free DOX and were preferentially retained in abdominal organs and in the peritoneal carcinomatosis. This feature is of clinical interest to target tumor deposits. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:43 / 52
页数:10
相关论文
共 31 条
[1]   Metabolite-derived artificial polymers designed for drug targeting, cell penetration and bioresorption [J].
Abdellaoui, K ;
Boustta, M ;
Vert, M ;
Manfait, M .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 6 (01) :61-73
[2]   Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].
Alberts, DS ;
Liu, PY ;
Hannigan, EV ;
OToole, R ;
Williams, SD ;
Young, JA ;
Franklin, EW ;
ClarkePearson, DL ;
Malviya, VK ;
DuBeshter, B ;
Adelson, MD ;
Hoskins, WJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955
[3]  
Araki H, 1999, ARTIF ORGANS, V23, P161
[4]  
Armstrong D. K., 2002, P AM SOC CLIN ONCOL
[5]   Pharmacokinetic and pharmacodynamic optimization of intraperitoneal chemotherapy [J].
Balthasar, JP ;
Fung, HL .
LIFE SCIENCES, 1996, 58 (07) :535-543
[6]  
Benoit L, 2000, GASTROEN CLIN BIOL, V24, P26
[7]   NEW FUNCTIONAL POLYAMIDES DERIVED FROM CITRIC-ACID AND L-LYSINE - SYNTHESIS AND CHARACTERIZATION [J].
BOUSTTA, M ;
HUGUET, J ;
VERT, M .
MAKROMOLEKULARE CHEMIE-MACROMOLECULAR SYMPOSIA, 1991, 47 :345-355
[8]  
CHAUFFERT B, 1992, GASTROEN CLIN BIOL, V16, P215
[9]   HPLC methods for the determination of bound and free doxorubicin, and of bound and free galactosamine, in methacrylamide polymer-drug conjugates [J].
Configliacchi, E ;
Razzano, G ;
Rizzo, V ;
Vigevani, A .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1996, 15 (01) :123-129
[10]   Enlarging the library of poly-(L-lysine citramide) polyelectrolytic drug carriers [J].
Couffin-Hoarau, AC ;
Boustta, M ;
Vert, M .
JOURNAL OF POLYMER SCIENCE PART A-POLYMER CHEMISTRY, 2001, 39 (20) :3475-3484